All In Biotech

Drug Trial Radar · NCT07023341

A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

36

Actual

Start

Jun 30, 2025

Primary completion

Jul 14, 2026

Study completion May 30, 2028

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM). Obstructive hypertrophic cardiomyopathy (oHCM) is a type of heart disease where the heart muscles become thicker than normal due to over contraction. This thickening makes it harder than normal due to over contraction. This thickening makes it harder for the heart to pump blood out to the rest of the body. In symptomatic oHCM people with the condition experience symptoms like shortness of breath, chest pain, fainting, high blood pressure and irregular heartbeats. The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM. It aims to reduce the activity of cardiac myosin, a protein that helps heart muscles to contract, and thereby preventing over contraction and muscle thickening. Although treatment options are available for symptomatic oHCM, there is still need for other treatment options that help target the root cause of the condition. In this study, researchers want to understand about the effects and long-term safety of aficamten in Japanese people with symptomatic oHCM. The main purpose of the study is to learn how well aficamten works in Japanese with symptomatic oCHM. For this, the researchers will check how participant's heart blood flow changes after 6 months of treatment. They do this by measuring the pressure needed for blood to leave the heart using a test called the left ventricular outflow tract (LVOT) gradient and a special breathing technique called Valsava maneuver. Researchers will also look for: * the number of participants who will have at least 1 level improvement on a scale doctors use to assess the effect of heart problems on daily activities after 3 and 6 months of treatment * the change in the impact of heart problems on participant's daily lives based on their feedback on a questionnaire called Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) after 3 and 6 months of treatment. This study will have 2 treatment periods: main treatment period and long-term treatment period. During the main treatment period, participants will take aficamten tablets once daily by mouth for up to 6 months. After completing this period, the participants who can join the long-term treatment period will continue taking aficamten until the drug becomes commercially available in Japan or the study ends. Each participant will be in the study as long as they benefit from the treatment. Participants will visit the study site: * once before the treatment starts * 9 times with a gap of 2 to 4 weeks between the visits during treatment under the main treatment period, and in the long-term treatment period, participants will visit almost every 3 months until the treatment ends. * then 2 more times with a gap of 1 month between the visits after the treatment ends. During the study, the study doctors and their team will: * check participant's health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) and echocardiogram (ECHO) * ask the participants questions about how they are feeling and what adverse events are they having An adverse event is any medical problem that a participant has during a study. Study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study. If the participant benefits from the treatment, treatment with aficamten after the end of the study might be possible.

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Interventions

  • BAY3723113Drug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Valsava LVOT-GTime frame: From baseline to Week 24

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Saiseikai Fukuoka General Hospital

    Fukuoka, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Saiseikai Kumamoto Hospital

    Kumamoto, Japan

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, Japan

  • Hyogo Prefectural HarimaHimeji General Medical Center

    Himeji, Hyōgo, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan

  • Iwate Prefectural Central Hospital

    Morioka, Iwate, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, Japan

  • SHOWA Medical University Fujigaoka Hospital

    Yokohama, Kanagawa, Japan

  • Kochi Medical School Hospital

    Nankoku, Kochi, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • University of the Ryukyus Hospital

    Ginowan, Okinawa, Japan

  • Matsushita Memorial Hospital

    Moriguchi, Osaka, Japan

  • National Cerebral and Cardiovascular Center

    Suita, Osaka, Japan

  • The University of Osaka Hospital

    Suita, Osaka, Japan

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, Japan

  • The University of Tokyo Hospital

    Bunkyo, Tokyo, Japan

  • Nippon Medical School Hospital

    Bunkyo-ku, Tokyo, Japan

  • Sakakibara Heart Institute

    Fuchū, Tokyo, Japan

  • Showa Medical University Koto Toyosu Hospital

    Koto-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.